TORONTO, June 17, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or “the Firm”) (CSE: SILO) (FRA: 3K70) (OTC: SILFF), a practical and psilocybin mushroom firm providing psychedelic wellness retreats, and Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon“), a biotechnology firm targeted on creating psychedelic medicines to deal with dependancy, have signed a referral settlement (the “Settlement”) to assist drive model consciousness of the Psychedelics Genetic Check equipment, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences Inc. (“HaluGen”), in addition to to empower visitors at Silo Wellness’ retreats to make knowledgeable selections by means of higher entry to details about themselves.
Silo Wellness is a publicly traded firm on the CSE with a consumer-facing platform for the sale of practical mushroom merchandise, psilocybin mushroom manufacturing in Jamaica, and the facilitation of psychedelic wellness retreats in each Jamaica and Oregon that incorporate quite a lot of psychedelic-augmented therapies. The intention of the Settlement is for Silo Wellness to offer referral and advertising providers for HaluGen’s Psychedelics Genetic Check, representing a possibility to increase entry and visibility for the take a look at, which was launched within the US on June 6, 2021. Silo Wellness will obtain compensation on every referral made to HaluGen.
The genetic take a look at, a primary of its type, identifies particular DNA biomarkers as a way to gauge the chance and potential of antagonistic reactions towards hallucinogenic medicine. The take a look at gives customers with customized studies and actionable insights, delivered instantly to 1’s smartphone, offering a handy and protected means to higher perceive a person’s sensitivity to classical psychedelics and ketamine. The take a look at additionally gives insights into the short- and long-term potential of psychedelic-induced dangers, corresponding to psychosis.
“We’re happy to be partnering with the revolutionary group at Silo Wellness who’re targeted on offering authorized entry to professionally administered wellness retreats which combine quite a lot of psychedelic therapies,” stated Entheon Biomedical Chief Government Officer Timothy Ko. “Elevated visibility and entry to the Psychedelics Genetic Check by means of Silo Wellness’ broad community furthers our dedication and skill to offer instruments and information to assist people make knowledgeable selections surrounding the consumption of psychedelics.”
“With this Entheon and HaluGen relationship, we will empower our visitors to make data-informed selections to hitch us for psychedelic experiences with ketamine and psilocybin and shortly, 5-MeO-DMT,” stated Silo Wellness Chief Government Officer Douglas Ok. Gordon. “It’s all about ‘set and setting’ with our psychedelic retreats, and one’s mindset is affected by their private anxieties concerning the medication and fears of potential antagonistic reactions. The extra alternative we can provide customers to entry details about themselves upfront of a session, the higher.
ABOUT SILO WELLNESS
The mission of Silo Wellness is to enhance well being and wellness by creating and introducing psychedelic medication to scale back trauma and enhance efficiency by destigmatizing the energetic compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, protected, and inexpensive alternate options to present medicines by facilitating entry into new and rising markets the place psychedelics are authorized by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing practical mushrooms.
Since inception, Silo Wellness’ actions have targeted on: (1) improvement and gross sales of practical mushroom tinctures; (2) improvement of a metered-dosing psilocybin nasal spray in Jamaica; (3) providing ketamine-assisted retreats in Oregon and psilocybin- and 5-MeO-DMT-assisted retreats in Jamaica; and (4) the cultivation of psilocybin psychedelic mushrooms in Jamaica.
For additional info on Silo Wellness, please contact:
Lisa Weser, Trailblaze PR
Silo Wellness Investor Relations:
Entheon is a biotechnology analysis and improvement firm dedicated to creating and commercializing a portfolio of protected and efficient N,N-dimethyltryptamine based mostly psychedelic therapeutic merchandise (“DMT Merchandise“) for the needs of treating dependancy and substance use problems. Topic to acquiring all requisite regulatory approvals and permits, Entheon intends to generate income by means of the sale of its DMT Merchandise to physicians, clinics and licensed psychiatrists in the US, sure nations within the European Union and all through Canada.
For extra info on Entheon, please contact:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Phone: +1 (778) 919-8615
For Entheon media inquiries, please contact Crystal Quast at:
Phone: +1 (647) 529-6364
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This information launch incorporates “forward-looking info” and “forward-looking statements” (collectively, “forward-looking statements”) throughout the which means of the relevant Canadian securities laws. All statements, aside from statements of historic reality, are forward-looking statements and are based mostly on expectations, estimates, and projections as on the date of this information launch. Any assertion that entails discussions with respect to predictions, expectations, beliefs, plans, projections, targets, assumptions, future occasions or efficiency (typically however not all the time utilizing phrases corresponding to “expects”, or “doesn’t count on”, “is predicted”, “anticipates” or “doesn’t anticipate”, “plans”, “finances”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such phrases and phrases or stating that sure actions, occasions or outcomes “might” or “may”, “would”, “would possibly” or “will” be taken to happen or be achieved) should not statements of historic reality and could also be forward-looking statements. On this information launch, forward-looking statements relate, amongst different issues, to: the Settlement, any gross sales and referrals between Silo Wellness and Entheon, administration’s expectation of the expansion of the psychedelic sector and the enterprise plans of Silo Wellness. Ahead-looking statements are essentially based mostly upon quite a few estimates and assumptions that, whereas thought of affordable, are topic to recognized and unknown dangers, uncertainties, and different elements which can trigger the precise outcomes and future occasions to vary materially from these expressed or implied by such forward-looking statements. Such elements embrace, however should not restricted to: normal enterprise, financial, aggressive, political and social uncertainties and the potential affect of COVID-19. There will be no assurance that such statements will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in such statements.
Readers mustn’t place undue reliance on the forward-looking statements and knowledge contained on this information launch. Silo Wellness assumes no obligation to replace the forward-looking statements of beliefs, opinions, projections, or different elements, ought to they alter, besides as required by regulation.
All info contained on this information launch with respect to Entheon and HaluGen was provided by Entheon for inclusion herein and Silo Wellness has relied on the accuracy of such info with out impartial verification.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.